Choi, Sangjoon
Hossain, Mofazzal
Lee, Hyun
Baek, Jina
Park, Hye Seon
Lim, Chae-Lyul
Han, DoYeon
Park, Taehyun
Kim, Jong Hyeok
Gong, Gyungyub
Kweon, Mi-Na
Lee, Hee Jin
Funding for this research was provided by:
Asan Institute for Life Sciences, Asan Medical Center (2018IL0169, 2018/9-794)
National Research Foundation of Korea (2021R1F1A1058175)
Article History
Received: 1 February 2024
Accepted: 25 March 2024
First Online: 17 April 2024
Declarations
:
: HJL is Chief Executive Officer of NeogenTc Corp. and has stock/stock options in NeogenTc Corp., and HSP and CLL are employed by Neogen Tc Corp. No other disclosures were reported.
: The study design was approved by the institutional review board of Asan Medical Center (2016 − 0935).